Replies to post #385148 on Amarin Corp Plc (AMRN)

[ziploc_1]

Bio...In the case of a combo with a Statin and Vascepa, a blister pack would seem to have the edge over a fixed dose combination.

1.It requires less research
2. It would be easier to manufacture
3. It could employ several different doses of statin combined with 4 grams of Vascepa
4. it would be easier to get FDA approval
5. It requires less investment of cash from Amarin
6. It further enhances the protection of the Vascepa EPA from oxidization...and thereby enhances shelf life

[Pharmacydude]

Bioinvestor
Maybe they are looking at a combination of the 2 ideas, like the suggestion I sent them 8 months ago:

https://drive.google.com/file/d/1toZTExgyvbSXJpqti8Q4WPL6Wzwuunl4/view?usp=drivesdk

[Meowza]

it only requires Phase 3

R-IT was a phase 3 study, which already showed that a combination of treatments with a statin plus Vascepa was safe and effective in reducing CVD.

This 'combination' has already received approval from the FDA...This IMO makes it unlikely that the FDA would now demand that Amarin repeat this study

Zip, you know I'm starting to wonder if KM knows what the hell he's talking about

lol!